Sanofi is set to acquire Vigil Neuroscience in a $470 million deal, thereby expanding its Neurological portfolio. This acquisition would provide Sanofi with Vigil’s investigational Alzheimer's Drug VG-3927 and allow them a foothold in a competitive arena. This has led to a surge in Vigil Neuroscience stocks. At the same time, Sanofi also reveals plans to invest at least $20 billion in the U.S by 2030. Their $130 million US 'flagship' office facility in New Jersey is now operational, housing 2000 employees. Despite the mass layoffs at IGM due to axing their pact with Sanofi, they remain on course amid tariff turmoil. Meanwhile, Sanofi continues to express commitment to sustainability and expanding healthcare access. The global healthcare giant announced new collaborations to improve disease management and awareness and was part of key deals this week along with Foxconn and Honeywell among others. However, criticism emerged related to Sanofi's U.S investment decision.
Sanofi News Analytics from Mon, 23 Sep 2024 12:06:18 GMT to Sun, 25 May 2025 00:53:06 GMT -
Rating 7
- Innovation 6
- Information 8
- Rumor -1
